Host and pathogen biomarkers for severe Pseudomonas aeruginosa infections

Journal of Infectious Diseases

Volumn 215, Issue , 2017, Pages S44-S51

  Juan, Carlos ^a   Peña, Carmen ^b   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^b HOSPITAL VIRGEN DE LOS LIRIOS   (Spain)

Author keywords

Antibiotic resistance; Biomarkers; High risk clones; Nosocomial infections; Pseudomonas aeruginosa; Virulence

Indexed keywords

BIOLOGICAL MARKER; CYTOTOXIN; ELASTASE; O ANTIGEN; ANTIINFECTIVE AGENT; GENETIC MARKER; TYPE III SECRETION SYSTEM; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BLOODSTREAM INFECTION; CLINICAL FEATURE; CLONE; DISEASE MARKER; DISEASE SEVERITY; DRUG USE; GENETIC TRAIT; GENOMIC ISLAND; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HUMAN; MARKER GENE; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEROTYPE; BLOOD; CROSS INFECTION; DRUG EFFECTS; GENETIC MARKER; GENETICS; MICROBIOLOGY; MOLECULAR CLONING; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; TYPE III SECRETION SYSTEM;

ANTI-BACTERIAL AGENTS; BIOMARKERS; CLONING, MOLECULAR; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENETIC MARKERS; HUMANS; O ANTIGENS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; TYPE III SECRETION SYSTEMS; VIRULENCE FACTORS;

EID: 85020374463     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw299     Document Type: Article

References (76)

1. Gellatly SL, Hancock RE. Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog Dis 2013;67:159-73.
2. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745-51.
3. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996;156:2121-6.
4. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-40.
5. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82.
6. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003;361:2068-77.
7. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011;19:419-26.
8. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(suppl 2):S82-9.
9. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582-610.
10. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011;2:65.
11. Cabot G, Ocampo-Sosa AA, Tubau F, et al. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study. Antimicrob Agents Chemother 2011;55:1906-11.
12. Juan C, Maciá MD, Gutiérrez O, Vidal C, Pérez JL, Oliver A. Molecular mechanisms of beta-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2005;49:4733-8.
13. Moya B, Dötsch A, Juan C, et al. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 2009;5:e1000353.
14. Berrazeg M, Jeannot K, Ntsogo Enguéné VY, et al. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. Antimicrob Agents Chemother 2015;59:6248-55.
15. Riera E, Cabot G, Mulet X, et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011;66:2022-7.
16. Hocquet D, Berthelot P, Roussel-Delvallez M, et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 2007;51:3531-6.
17. Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 2015;28:337-418.
18. Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S. Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance. Antimicrob Agents Chemother 2013;57:1361-8.
19. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
20. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol 2014;5:643.
21. Muller C, Plésiat P, Jeannot K. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2011;55:1211-21.
22. Patel G, Bonomo RA. Status report on carbapenemases: challenges and prospects. Expert Rev Anti Infect Ther 2011;9:555-70.
23. Oliver A, Mulet X, López-Causapé C, Juan C. The increasing threat of Pseudomonas aeruginosa high-risk clones. Drug Resist Updat 2015;21-22:41-59.
24. Peña C, Cabot G, Gómez-Zorrilla S, et al. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections. Clin Infect Dis 2015;60:539-48.
25. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gramnegative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014;43:328-34.
26. Zilberberg MD, Shorr AF. Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med 2013;8:559-63.
27. Spencer DH, Kas A, Smith EE, et al. Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol 2003;185:1316-25.
28. He J, Baldini RL, Déziel E, et al. The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes. Proc Natl Acad Sci USA 2004;101:2530-5.
29. Harrison EM, Carter ME, Luck S, et al. Pathogenicity islands PAPI-1 and PAPI-2 contribute individually and synergistically to the virulence of Pseudomonas aeruginosa strain PA14. Infect Immun 2010;78:1437-46.
30. Battle SE, Meyer F, Rello J, Kung VL, Hauser AR. Hybrid pathogenicity island PAGI-5 contributes to the highly virulent phenotype of a Pseudomonas aeruginosa isolate in mammals. J Bacteriol 2008;190:7130-40.
31. Battle SE, Rello J, Hauser AR. Genomic islands of Pseudomonas aeruginosa. FEMS Microbiol Lett 2009;290:70-8.
32. Singh G, Srinivasan R, Cheng J, et al. Rearrangement of a large novel Pseudomonas aeruginosa gene island in strains isolated from a patient developing ventilator-associated pneumonia. J Clin Microbiol 2014;52:2430-8.
33. Jimenez PN, Koch G, Thompson JA, Xavier KB, Cool RH, Quax WJ. The multiple signaling systems regulating virulence in Pseudomonas aeruginosa. Microbiol Mol Biol Rev 2012;76:46-65.
34. Gooderham WJ, Hancock RE. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol Rev 2009;33:279-94.
35. Bleves S, Viarre V, Salacha R, Michel GP, Filloux A, Voulhoux R. Protein secretion systems in Pseudomonas aeruginosa: A wealth of pathogenic weapons. Int J Med Microbiol 2010;300:534-43.
36. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 2009;7:654-65.
37. Martínez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002;15:647-79.
38. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010;8:260-71.
39. Balasubramanian D, Schneper L, Kumari H, Mathee K. A dynamic and intricate regulatory network determines Pseudomonas aeruginosa virulence. Nucleic Acids Res 2013;41:1-20.
40. Baquero F. From pieces to patterns: evolutionary engineering in bacterial pathogens. Nat Rev Microbiol 2004;2:510-8.
41. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 2013;26:185-230.
42. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011;35:736-55.
43. Linares JF, López JA, Camafeita E, Albar JP, Rojo F, Martínez JL. Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa. J Bacteriol 2005;187:1384-91.
44. Martínez-Ramos I, Mulet X, Moyá B, Barbier M, Oliver A, Albertí S. Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing. Antimicrob Agents Chemother 2014;58:2426-9.
45. Sawa T, Shimizu M, Moriyama K, Wiener-Kronish JP. Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review. Crit Care 2014;18:668.
46. Skurnik D, Roux D, Cattoir V, et al. Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing. Proc Natl Acad Sci USA 2013;110:20747-52.
47. Mulet X, Cabot G, Ocampo-Sosa AA, et al. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother 2013;57:5527-35.
48. Gómez-Zorrilla S, Camoez M, Tubau F, et al. Antibiotic pressure is a major risk factor for rectal colonization by multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Antimicrob Agents Chemother 2014;58:5863-70.
49. Gómez-Zorrilla S, Camoez M, Tubau F, et al. Prospective observational study of prior rectal colonization status a predictor for subseqüent development of Pseudomonas aeruginosa clinical infections. Antimicrob Agents Chemother 2015;59:5213-9.
50. Joo EJ, Kang CI, Ha YE, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist 2011;17:305-12.
51. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrugresistant Pseudomonas aeruginosa bacteremia on patients outcomes. Antimicrobial Agents Chemother 2010;54:3717-22.
52. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibioticresistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49:760-6.
53. Peña C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012;56:1265-72.
54. Peña C, Suarez C, Ocampo-Sousa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis 2013;57:208-16.
55. Ulloa L, Tracey KJ. The "cytokine profile": a code for sepsis. Trends in Mol Med 2005;11:56-63.
56. Osuchowski MF, Connett J, Welch K, Granger J, Remick DG. Stratification is the key: inflammatory biomarkers accurately direct immune-modulatory therapy in experimental sepsis. Crit Care Med 2009;37:1567-73.
57. Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat Rev Genet 2012;13:175-88.
58. Christaki E, Giamarellos-Bourboulis EJ. The complex pathogenesis of bacteremia. From antimicrobial clearance mechanisms to the genetic background of the host. Virulence 2014;5:57-65.
59. Lorè NI, Iraqi FA, Bragonzi A. Host genetic diversity influences the severity of Pseudomonas aeruginosa pneumonia in the Collaborative Cross mice. BMC Genetics 2015;16:106.
60. Hirsch EB, Cottreau JM, Chang KT, Caeiro JP, Johnson ML, Tam VH. A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis 2012;72:97-102.
61. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH. Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother 2011;66:1311-7.
62. Gómez-Zorrilla S, Juan C, Cabot G, et al. Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. Int J Antimicrob Agents 2016;47:368-74.
63. Sullivan E, Bensman J, Lou M, Agnello M, Shriner K, Wong-Beringer A. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa. Crit Care Med 2014;42:48-56.
64. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. Clinical outcome of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012;40:1157-63.
65. Hattemer A, Hauser A, Diaz M, et al. Bacterial and Clinical characteristics of health-care and community-acquired bloodstream infections due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013;57:3969-75.
66. Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with por clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002;30:521-8.
67. Roy-Burman A, Saver RH, Racine S, et al. Type III secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001;183:1767-74.
68. Agnello M, Wong-Beringer A. Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PLoS One 2012;7:e42973.
69. Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 2008;20:714-20.
70. Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008;14:330-6.
71. Cabot G, Ocampo-Sosa AA, Domínguez MA, et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob Agents Chemother 2012;56:6349-57.
72. Cholley P, Thouverez M, Hocquet D, Van der Mee-Marquet N, Talon D, Bertrand X. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol 2011;49:2578-83.
73. Maatallah M, Cheriaa J, Backhrouf A, et al. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 2011;6:e25617.
74. Edelstein MV, Skleenova EN, Shevchenko OV, et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013;13:867-76.
75. Lu Q, Eggimann P, Luyt CE, et al. Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes. Crit Care 2014;18:R17.
76. Jeong SJ, Yoon SS, Bae IK, Jeong SH, Kim JM, Lee K. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Diagn Microbiol Infect Dis 2014;80:130-5.